Considering the pivotal role of tumor immune microenvironment features and components in tumor proliferation, metastasis, and the development of drug resistance,48–52 it is valuable to investigate the relationships between tumor immune microenvironment features and components and efficacy of third-generation EGFR-TKIs in patients with EGFR-mutant NSCLC. This evidence concerns the gene EGFR and neoplasm.